Table 3.

Results of secondary endpoints at baseline, month 1 and end of study period (≥3 months). N = 51

Variable	Visit	N = 51	Value	Change in value
			Mean ± SD	Mean ± SD	P value
TBUT (second)	Baseline		3.0 ± 1.8	–	–
	Month 1		4.1 ± 2.9	1.1 ± 2.5	0.003
	End of study period		3.7 ± 2.5	0.7 ± 2.1	0.017
Hyperaemia score
Bulbar conjunctiva	Baseline		1.7 ± 0.5	–	–
	Month 1		1.6 ± 0.6	−0.2 ± 0.6	0.028
	End of study period		1.5 ± 0.5	−0.3 ± 0.5	0.001
Palpebral conjunctiva	Baseline		1.8 ± 0.6	–	–
	Month 1		1.8 ± 0.6	−0.1 ± 0.6	0.497
	End of study period		1.5 ± 0.5	−0.3 ± 0.6	0.001
Subjective symptoms (OSD score)
Eye discharge	Baseline		0.2 ± 0.4	–	–
	Month 1		0.2 ± 0.4	0.0 ± 0.5	0.799
	End of study period		0.2 ± 0.4	−0.1 ± 0.5	0.290
Eye pain	Baseline		0.1 ± 0.4	–	–
	Month 1		0.0 ± 0.2	−0.1 ± 0.4	0.261
	End of study period		0.0 ± 0.0	−0.1 ± 0.4	0.058
Foreign body sensation	Baseline		0.4 ± 0.6	–	–
	Month 1		0.2 ± 0.4	−0.1 ± 0.7	0.164
	End of study period		0.0 ± 0.2	−0.3 ± 0.5	<0.001
Irritation (burning/stinging)	Baseline		0.3 ± 0.7	–	–
	Month 1		0.2 ± 0.4	−0.2 ± 0.8	0.146
	End of study period		0.0 ± 0.1	−0.3 ± 0.7	0.006
Itching	Baseline		0.5 ± 0.8	–	–
	Month 1		0.2 ± 0.4	−0.3 ± 0.8	0.010
	End of study period		0.1 ± 0.3	−0.4 ± 0.8	<0.001
Photophobia	Baseline		0.4 ± 0.6	–	–
	Month 1		0.1 ± 0.3	−0.3 ± 0.7	0.011
	End of study period		0.2 ± 0.4	−0.2 ± 0.6	0.009
Tearing	Baseline		0.2 ± 0.5	–	–
	Month 1		0.2 ± 0.4	0.0 ± 0.6	1.000
	End of study period		0.3 ± 0.5	0.0 ± 0.5	0.799
Total score	Baseline		2.2 ± 2.7	–	–
	Month 1		1.2 ± 1.3	−0.9 ± 2.8	0.019
	End of study period		0.7 ± 1.1	−1.4 ± 2.3	<0.001
IOP (mmHg)	Baseline		14.4 ± 3.2	–	–
	Month 1		14.2 ± 3.5	−0.2 ± 2.7	0.645
	End of study period		14.3 ± 2.8	−0.1 ± 3.1	0.874

IOP, intraocular pressure; OSD, ocular surface disease; TBUT, tear break‐up time.